Under German law, if a product with an infringing item is sold by a company with a presence in Germany, that company is liable for infringement, even if that product never crosses the German border. For example, a German company orders an infringing product from a manufacturer in Taiwan for delivery to Australia.

In Germany the onus is on a potential infringer to ensure that none of their products used infringe a German patent.

As to extending the life of any patent, there are limited circumstances in which this can occur, mainly pharmaceutical patents, and I can see no basis for an extension of the MMP Portfolio. Corrections welcomed.

.

.

Be well